Quark Pharmaceuticals announced this week that it has formed a collaboration with Japan's Nitto Denko to develop siRNA-based drugs for fibrotic diseases.
The deal, Quark said, will combine its expertise and intellectual property related to siRNA design with Nitto Denko's drug-delivery technologies.
The collaboration will have an initial budget in the "double-digit" millions of dollars, and is expected to yield an investigational new drug application by early 2012, Quark added.
Additional terms were not disclosed.